Last reviewed · How we verify
HSK39004 Dry Powder Inhaler Simulant
HSK39004 Dry Powder Inhaler Simulant is a Small molecule drug developed by Haisco Pharmaceutical Group Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | HSK39004 Dry Powder Inhaler Simulant |
|---|---|
| Sponsor | Haisco Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HSK39004 Dry Powder Inhaler Simulant CI brief — competitive landscape report
- HSK39004 Dry Powder Inhaler Simulant updates RSS · CI watch RSS
- Haisco Pharmaceutical Group Co., Ltd. portfolio CI
Frequently asked questions about HSK39004 Dry Powder Inhaler Simulant
What is HSK39004 Dry Powder Inhaler Simulant?
HSK39004 Dry Powder Inhaler Simulant is a Small molecule drug developed by Haisco Pharmaceutical Group Co., Ltd..
Who makes HSK39004 Dry Powder Inhaler Simulant?
HSK39004 Dry Powder Inhaler Simulant is developed by Haisco Pharmaceutical Group Co., Ltd. (see full Haisco Pharmaceutical Group Co., Ltd. pipeline at /company/haisco-pharmaceutical-group-co-ltd).
What development phase is HSK39004 Dry Powder Inhaler Simulant in?
HSK39004 Dry Powder Inhaler Simulant is in Phase 2.